Probatebeta
Target

PPARG

Peroxisome proliferator-activated receptor gamma

As of the edition of 20 October 2026, PPARG (peroxisome proliferator-activated receptor gamma, UniProt P37231) has 38 drugs tested at it and 39 companies on the list, 16 on route A and 8 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P37231
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
Inside the cell
Solved structures
380
Disease areas
Nutrition and metabolism; Hormones; Digestive system; Cancer; Urinary and reproductive; Heart and blood vessels; Pregnancy and women's health; Immune system
Registered trials of its drugs
818

Drugs at this target

StatusCount
Marketed10
Active5
Went quiet14
Stopped9
Total38
DrugStatusFurthest phaseUS protection
PioglitazoneMarketedPhase 4none listed
RosiglitazoneMarketedPhase 4none listed
MesalamineMarketedPhase 4Ends 2027
Bardoxolone methylStoppedPhase 3none listed
LobeglitazoneMarketedPhase 4none listed
AleglitazarStoppedPhase 3none listed
SaroglitazarMarketedPhase 4none listed
BezafibrateMarketedPhase 4none listed
ChiglitazarActivePhase 3none listed
TesaglitazarStoppedPhase 3none listed
EfatutazoneStoppedPhase 2none listed
MK-0767StoppedPhase 3none listed

12 of 38 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A16
Route B8
Engaged6
Undetermined9
Total on the list39
Three companies on route A or B, with the route only
CompanyRoute
Bristol Myers SquibbRoute A
Merck & Co.Route A
AstraZenecaRoute A

The other 36 companies at PPARG

In the product

39 companies in all; 36 are not named here, and no score is.

See the 39 companies at PPARG, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at PPARG

Other targets in nutrition and metabolism

Companies holding approvals at PPARG